Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

TerrAscend Corp. TRSSF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score
55/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$2.93
+70.3%

TerrAscend Corp. (TRSSF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $1.72. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is TRSSF = $3 (+70.3% upside).

Financials: revenue is $261M, +3.2%/yr average growth. Net income is $81M (loss), growing at +26.1%/yr. Net profit margin is -31.2% (negative). Gross margin is 52.3% (+11.3 pp trend).

Balance sheet: total debt is $47M against $99M equity (Debt-to-Equity (D/E) ratio 0.48, conservative). Current ratio is 1.38 (adequate). Debt-to-assets is 8.5%. Total assets: $557M.

Analyst outlook: 1 / 3 analysts rate TRSSF as buy (33%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 73/100 (Pass), Past 0/100 (Fail), Health 83/100 (Pass), Moat 64/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$2.93
▲ 70.35% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for TerrAscend Corp., the average price target is $2.93, with a high forecast of $3.00, and a low forecast of $2.85.
Highest Price Target
$3.00
Average Price Target
$2.93
Lowest Price Target
$2.85

TRSSF SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 73/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 83/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 64/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TRSSF

✓
VALUE Pass
100/100
TRSSF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +74.4% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
73/100
TRSSF: +3.2%/yr revenue is, +26.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
83/100
Balance sheet TRSSF: Debt-to-Equity (D/E) ratio 0.48 (conservative), Current ratio is 1.38 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
64/100
TRSSF: Gross margin is 52.3% (+11.3 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 64/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 1 / 3 analysts rate TRSSF as buy (33%). Analyst consensus target is $3 (+74.4% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
TRSSF: Net profit margin is -31.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range1.0-3.09
Volume125.79K
Avg Volume (30D)140.89K
Market Cap$601.91M
Beta (1Y)2.00
Share Statistics
EPS (TTM)-0.29
Shares Outstanding$301.08M
IPO Date2017-11-17
Employees972
CEOZiad Ghanem
Financial Highlights & Ratios
Revenue (TTM)$260.56M
Gross Profit$136.32M
EBITDA$-46.44M
Net Income$-81.33M
Operating Income$42.02M
Total Cash$37.41M
Total Debt$47.32M
Net Debt$9.9M
Total Assets$557.38M
Price / Earnings (P/E)-5.9
Price / Sales (P/S)2.31
Analyst Forecast
1Y Price Target$2.93
Target High$3.00
Target Low$2.85
Upside+70.1%
Rating ConsensusHold
Analysts Covering3
Buy 33% Hold 67% Sell 0%
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA88105E1088

Price Chart

Track all markets on TradingView
TRSSF
TerrAscend Corp. ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic
1.00 52WK RANGE 3.09

People Also View

GTBIF
GTBIF
Green Thumb Industries Inc.
$7.16
+5.92%
 CCHWF
CCHWF
Columbia Care Inc.
$0.94
-21.71%
 VRNOF
VRNOF
Verano Holdings Corp.
$1.30
+8.33%
 JUSHF
JUSHF
Jushi Holdings Inc.
$0.55
+8.58%
 AYRWF
AYRWF
Ayr Wellness Inc.
$0.01
-6.15%
 LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message